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 The microsomal triglyceride transfer protein (MTTP) is 
essential for formation of apolipoprotein B (apoB)-con-
taining lipoproteins. The liver and the intestine have the 
highest tissue expression of  MTTP and secrete triacylglyc-
erol (TAG)-rich VLDLs and chylomicrons, respectively 
( 1 ).  MTTP is also expressed in other cells such as cardio-
myocytes ( 2 ) and macrophages ( 3 ). The heart secretes 
apoB100-containing lipoproteins and it has been proposed 
that cardiac lipoprotein secretion protects the heart against 
accumulation of lipids that are toxic to the myocardium 
( 4 ). This theory is supported by the fi nding that  MTTP ex-
 Abstract  Promoter polymorphisms in microsomal triglyc-
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case-control study including a total of 544 IHD patients and 
544 healthy control subjects.  We concluded that carriers 
of the minor -164C allele have lower expression of  MTTP in 
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ing ( 6 ). Of these individuals, six were heterozygous for the  MTTP 
polymorphisms, six were homozygous for the major alleles and 
four were homozygous for the minor alleles. Basic characteristics 
are shown in Supplementary  Table I . The study was approved by 
the ethics committee at the Karolinska Institutet, Stockholm, 
Sweden. Approximately 100 ml blood was drawn from each indi-
vidual and primary blood monocytes were isolated using Ficoll-
Paque according to the manufacturer’s instructions (GE 
Healthcare Bio-Sciences). The isolated primary cells were differ-
entiated into macrophages by PMA treatment as described ( 11 ). 
To allow complete differentiation, the cells were cultured for 
anoth er 60 h at 37°C. The macrophages were cultured under 
basal conditions. Total RNA was isolated and reverse transcribed 
using Superscript II (Invitrogen). Subjects gave their informed 
consent to participate. 
 Allele-specifi c gene expression assay 
 The Ile128Thr polymorphism in  MTTP was used as a marker 
for the allele-specifi c expression of the -493G>T and -164T>C 
polymorphisms. Pyrosequencing technology (Biotage) was used 
to compare the relative allelic expression in subjects heterozy-
gous for these three SNPs. A fragment of approximately 100 base 
pairs surrounding the Ile128Thr polymorphism was amplifi ed by 
PCR from cDNA or genomic DNA. Forward primers were biotiny-
lated. Single-stranded PCR fragments were separated and se-
quenced with the use of PyroGold reagents and the PSQ 96MA 
Pyrosequencing machine and software version 2.0.2. To normal-
ize signals from different fl uorescent dyes, a standard curve for 
the cDNA assay was used as shown in Supplementary  Fig. I . Ge-
nomic DNA with expected perfect 1:1 allele ratio was included as 
a control. The method has been described elsewhere ( 12 ). 
Primer sequences are given in  Table 1 . 
 Transient transfections and luciferase assay 
 Minimal promoter constructs containing the -164T>C SNP 
(-179 to -148) were based on four sets of complementary oligo-
nucleotides. The oligonucleotides were annealed and cloned 
into the pGL3-promoter vector (SDS Promega) using  Bgl II and 
 BamH 1 restriction sites as described ( 13 ). Longer promoter frag-
ments were amplifi ed from genomic DNA from two subjects ho-
mozygous for the major or minor alleles of the -493G>T and 
-164T>C SNPs, respectively. The amplifi ed  MTTP promoter re-
gion spans from -593 to +27, relative to the transcriptional start 
site. For cloning purposes, the primers were fl anked by  Nhe 1 and 
 Bgl II restriction sites. The amplifi ed PCR products were cloned 
into pGL3-basic vector (SDS Promega). The longer promoter 
fragments includes proximal promoter and the transcription 
start site and do not require a reporter that contains promoter 
sequence to generate transcriptional activity, as measured by the 
luciferase assay. All constructs were verifi ed by DNA sequencing 
according to the manufacturer’s protocol (ABI). Primer and oli-
gonucleotide sequences are given in  Table 1 . 
 The cell lines used in this study (HepG2, Huh7, and HeLa) 
were maintained in Dulbecco’s modifi ed Eagle’s medium, sup-
plemented with 10% FBS and 0.6% penicillin-streptomycin, in 
6-well plates. The Dual Luciferase Reporter Assay System from 
SDS Promega was used for the transfection assays. The cells re-
ceived fresh medium 3 h before transfection. The cells were then 
cotransfected with 3   g/well CaCl 2 precipitated pGL3-promoter 
or pGL3-basic vector and 1   g/well control vector pRL-TK. The 
luciferase and  Renilla luciferase activities were measured 48 h af-
ter transfection according to the manufacturer’s protocols. As-
says were performed under basal conditions or in the presence of 
100 nM insulin. Insulin was added 48 h prior to harvesting the 
cells. All assays were performed in triplicate. 
pression is inversely correlated with the concentration of 
TAGs in the myocardium. Thus, ischemia-induced TAG 
accumulation in the myocardium might be mitigated by 
increased  MTTP expression in the myocardium ( 5 ). 
 The -493G>T single nucleotide polymorphism (SNP) in 
 MTTP (rs1800591) has been associated with metabolic 
traits and ischemic heart disease (IHD) ( 6 ). Homozygosity 
for the minor -493T allele appeared to confer an increased 
risk for IHD in two studies, the West of Scotland Coronary 
Prevention Study (WOSCOPS) and the Uppsala Longitu-
dinal Study of Adult Men (ULSAM), together comprising 
680 patients with IHD ( 6 ). 
 The -493G>T polymorphism is in linkage disequilibrium 
(LD) with two other SNPs in  MTTP , the -164T>C (rs1800804) 
and Ile128Thr (rs3816873) ( 7, 8 ). It is not known which of 
these three SNPs are functional in vivo, and few studies 
have addressed tissues other than the liver and intestine. 
The  MTTP promoter is well characterized, and it has been 
shown that the fi rst 200bp in the proximal promoter deter-
mines the basal expression and regulation of  MTTP ( 9 ). 
 We hypothesized that  MTTP promoter polymorphisms 
alter the expression of the gene in the heart, thereby 
affect ing lipid accumulation in the myocardium and thus, 
susceptibility to ischemia. Against this background, we 
investigat ed the in vivo allele-specifi c mRNA expression of 
 MTTP in human heart, liver, and macrophages. We also 
characterized the underlying mechanism to the allele-
specifi c gene expression and investigated the association 
between the  MTTP polymorphisms and IHD in a Swedish 
case-control study. 
 MATERIALS AND METHODS 
 Biopsies from the human heart 
 Nine left ventricular biopsies were obtained from subjects who 
were heterozygous for the -493G>T, -164T>C, and Ile128Thr 
SNPs. The biopsies were from a biobank of left ventricular biop-
sies taken from patients undergoing heart valve surgery. The nine 
biopsies obtained were all from patients with tricuspid valves. The 
nine patients were of Caucasian origin and none of them had type 
2 diabetes (T2D). Basic characteristics are shown in Supplemen-
tary  Table I . Subjects had given their written informed consent to 
participate. The study was approved by the ethics committee at 
the Karolinska Institutet, Stockholm, Sweden. 
 Liver biopsies from individuals with hepatic steatosis 
 Liver samples were obtained from 25 Caucasian subjects with 
various degrees of liver steatosis. Total RNA was isolated and 
cDNA generated according to standard protocols. Twelve of 
these individuals were found to be heterozygous for the MTTP 
polymorphisms and were subsequently examined. None of the 
12 individuals suffered from T2D. Basic characteristics are shown 
in Supplementary  Table I . Subjects had given their written in-
formed consent to participate. The study was approved by the 
ethics committee of the Helsinki University Hospital ( 10 ). 
 Primary monocytes from healthy individuals 
 A total of 16 healthy individuals with known genotypes for the 
-493G>T, -164T>C and Ile128Thr polymorphisms were recruited 
among Caucasian participants from a previous population screen-
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genetic susceptibility, environmental factors, lifestyle, gender, and 
established risk factors in cardiovascular disease. The patients were 
survivors of acute coronary syndrome (ACS) and were identifi ed 
from the same source population as the sampled cohort. There 
was no lower age limit for the fi rst event and the upper age limit 
was 75. ACS comprises both acute myocardial infarction [Interna-
tional Classifi cation of Diseases (ICD) 10: I21.0-I21.9] and unstable 
angina pectoris (ICD 10: I20.0). Previously-known coronary cases 
with new attacks as well as fi rst time patients were included. The 
patients and controls were 61.1 ± 8.4 and 61.2 ± 8.4 years old, re-
spectively, and 28% were women. The participants had given their 
informed written consent to participate. The study was approved 
by the local ethics committee. Full description of the study is avail-
able at www.sahlgrenska.gu.se/intergene ( 16 ). 
 Genotyping 
 Genomic DNA from subjects included in the case-control co-
hort and in the allele-specifi c gene expression assay was isolated 
from venous blood according to standard protocols. The subjects 
were genotyped for the -493G>T (rs1800591G>T) and the -164T>C 
(rs1800804T>C) polymorphisms by TaqMan Technology (ABI). 
The call rates were above 96% for both the -493G>T and -164T>C 
assays. The -493G>T and -164T>C position are relative  MTTP tran-
scription start site according to RefSeq NM_000253.1. 
 Statistical analyses 
 Statistical analyses were conducted using the SAS 9.1.3 soft-
ware (SAS Institute, Inc., Cary, NC). Hardy-Weinberg equilib-
rium and differences in genotype distributions were assessed 
using   2 tests. Pairwise linkage disequilibrium was estimated us-
ing a maximum-likelihood Expectation Maximization algorithm 
implemented in the Haploview 4.0 software ( 17 ). Continuous 
variables that did not adhere to a normal distribution were nor-
malized by logarithmic transformation prior to statistical analy-
 TABLE 1. Primers and oligonucleotides used in current study 
 Used in Experiment  Oligonucleotide Sequence (5 ′  → 3 ′ )  Position  MTTP Region  Direction 
 Allele-Specifi c Gene Expression 
Amplifi cation of genomic 
 DNA and cDNA
GAGAAGAGCATCTTCAAAGG a +378 – +397 Exon 3 Forward
Amplifi cation of genomic 
 DNA
GAGAAAAAGTTGTGGAATCTAA +479 (+13) – +479 (+35) b Intron 3 Reverse
Amplifi cation of cDNA TTCTATGGCCACTGCCTCATT +504 – +524 Exon 4 Reverse
Sequencing of genomic DNA CCTTTACCTTTCCATGG +470 – +479 (+7) Exon 3 – Intron 3 Reverse
Sequencing of cDNA CTTTGACCTTTCCATGG +470 – +486 Exon 3 – Exon 4 Reverse
 Luciferase Assay 
Minimal promoter construct  GATCC TTAAAGTTTCCTCA T TGGGTGAAAAAAATTA -178 – -148 Promoter Forward
Minimal promoter construct  GATCT TAATTTTTTTCACCCA A TGAGGAAACTTTAAG -178 – -148 Promoter Reverse
Minimal promoter construct  GATCC TTAAAGTTTCCTCA C TGGGTGAAAAAAATTA -178 – -148 Promoter Forward
Minimal promoter construct  GATCT TAATTTTTTTCACCCA G TGAGGAAACTTTAAG -178 – -148 Promoter Reverse
Amplifi cation of long 
 promoter construct
 GCTAG CGCTGATTTGCTCCAAC -592 – -577 Promoter Forward
Amplifi cation of long 
 promoter construct
 AGATCT TTCAATGGCAGCCAGT +9 – +27 Exon 1 Reverse
 EMSA 
  164T oligonucleotide CATTTAAAGTTTCCTCA T TGGGTGAAA -181 – -155 Promoter Forward
  164T oligonucleotide TTTCACCCA A TGAGGAAACTTTAAATG -181 – -155 Promoter Reverse
  164C oligonucleotide CATTTAAAGTTTCCTCA C TGGGTGAAA -181 – -155 Promoter Forward
  164C oligonucleotide TTTCACCCA G TGAGGAAACTTTAAATG -181 – -155 Promoter Reverse
LDL-SRE oligonucleotide TTGAAAATCACCCCACTGCA  –  – Forward
LDL-SRE oligonucleotide TGCAGTGGGGTGATTTTCAA  –  – Reverse
C/EBP consensus 
 oligonucleotide
TGCAGATTGCGCAATCTGCA  –  – Forward
C/EBP consensus 
 oligonucleotide
TGCAGATTGCGCAATCTGCA  –  – Reverse
Positions in the  MTTP gene are given relative to transcription start site (+1) according to NM_000253.1 (mRNA).  a primer is 5 ′ -biotinylated,  b 
primer is located in intronic region,  c primer covers the exon/intron boundary. Rs1800804:T>C is indicated by bold characters. Enzymatic restriction 
sites are underlined ( Bgl II,  Nhe I,  BamH I).
 In order to investigate if CCAAT/enhancer binding proteins 
(C/EBPs) had any direct effect in the allele-specifi c expression of 
MTTP, HeLa cells, which do not express  MTTP and only express 
 C/EBP at low levels, were cotransfected with plasmids comprising 
the  MTTP promoter (-593 to +27) and PCMV5 expression vectors 
containing  C/EBP  ,  C/EBP  , or  C/EBP  . The C/EBP expression 
vectors were a kind gift from Dr. Magnus Nord, Karolinska Insti-
tutet. Transient transfections and luciferase assay were performed 
as described above. 
 EMSA 
 For electrophoretic mobility shift assays (EMSAs), comple-
mentary oligonucleotides containing the -164 polymorphic site, 
C/EBP consensus, and a sterol response element (SRE), which 
binds sterol response element binding protein 1 (SREBP-1), were 
annealed. Nuclear extracts were prepared from HepG2 or Huh7 
liver cell lines as described ( 14 ), and competitive EMSAs were 
performed with labeled oligonucleotide corresponding to 50,000 
cpm and 100-fold excess for competition with cold oligonucle-
otide. To investigate the potential binding of SREBP-1, HepG2 
cells were transfected with an SREBP-1 expression vector before 
harvesting. Successful cloning was verifi ed by sequencing (ABI). 
For the supershift assay, 1   g/lane of human anti-SREBP-1 anti-
body was added to the mixture and incubated for 10 min at room 
temperature before loading onto the gel. The antibodies were a 
kind gift from Dr. Jay Horton, Southwestern Medical Center, 
Dallas, TX. The EMSA experiment was performed as described 
( 15 ). Primer sequences are shown in  Table 1 . 
 Case-control study (INTERGENE) 
 The case-control study is part of the INTERGENE study and in-
cludes 544 validated IHD patients and 544 age- and sex-matched 
control subjects living in the Västra Götaland region of Sweden. 
INTERGENE is a cohort designed to study the interplay between 
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sulin is known to downregulate the  MTTP promoter 
activity ( 18 ) and the insulin-response element is present in 
the proximal promoter of  MTTP (bp -123 to -112) ( 9 ); 
therefore, the cells were treated with 100 nM insulin as a 
positive control. Addition of insulin further decreased the 
 MTTP promoter activity by 30% ( P = 0.004) compared 
with untreated cells, showing that the reporter gene con-
structs responded to insulin treatment as expected ( Fig. 
2 ). The difference in promoter activity between the major 
-493G/-164T alleles and the minor -493T/-164C alleles 
was attenuated when cells were treated with insulin ( Fig. 
2 ). The in vitro results are in agreement with the in vivo 
results and indicate that the minor -164C allele mediates 
the decreased transcriptional activity. 
 Allele-specifi c binding of C/EBP to the -164T>C 
polymorphic site 
 The -164 polymorphic site comprises both a putative 
C/EBP response element and a putative SRE ( Fig. 3A ). 
The major -164T allele is homologous to the C/EBP re-
sponse element. MatInspector predicted a C/EBP binding 
site across the -164 polymorphic region when the pro-
moter sequence containing the major T-allele was used 
(Core Similarity = 1.000). When the T allele was changed 
to the C allele, MatInspector could not predict the C/EBP 
binding site. MatInspector did not predict any SRE across 
the -164 polymorphic site with either the T or C allele, 
respective ly. However, earlier studies showed that a puta-
tive SRE similar to the one found in the LDL-receptor 
( LDLR ) gene is present across the -164 region ( 9, 19 ). The 
minor -164C allele shows higher homology with the puta-
tive SRE ( Fig. 3A ). EMSAs were performed to investigate 
potential binding of these nuclear factors. 
ses. Differences between groups were estimated by unpaired  t -test 
and one-way ANOVA using Fisher’s protected least signifi cant 
difference test for post hoc analysis. Odds ratios (ORs) with cor-
responding 95% confi dence intervals (CI) were calculated using 
logistic regression analysis and adjusted for age and gender. Lin-
ear regression was applied on the standard curve used in the al-
lele-specifi c gene expression assay. The Wilcoxon sign rank test 
was employed to detect any differences in allelic ratio as mea-
sured by pyrosequencing technology.  P  values < 0.05 were consid-
ered signifi cant. 
 RESULTS 
 Allele-specifi c gene expression of MTTP in the human 
heart, liver, and macrophages 
 To investigate whether the -493G>T and -164T>C SNPs 
infl uence transcriptional activity in vivo, the allele-specifi c 
gene expression of  MTTP was analyzed by pyrosequencing 
technology in human tissue biopsies from the heart, liver, 
and macrophages. 
 The pyrosequencing technology was employed because 
the method can detect small differences in relative gene ex-
pression from each chromosome with high accuracy. Analy-
ses need to be performed in material from individuals 
heterozygous for the polymorphism(s) of interest. Any im-
balance in expression levels between two alleles is, thus, 
measured within the same individual, hence, minimizing 
the  cis - and  trans -acting effects. The allele-specifi c gene ex-
pression of  MTTP was measured in individuals heterozygous 
for the -493G>T, -164T>C, and Ile128Thr polymorphisms 
that are in perfect LD. The results show that the expression 
of the minor alleles of the  MTTP polymorphisms was signifi -
cantly lower compared with the major alleles in the heart 
( P = 0.004), liver ( P = 0.001), and macrophages ( P = 0.031) 
( Fig. 1 ). Genomic DNA from the same individuals was used 
as control and the allele ratio for the DNA was 50% as ex-
pected ( Fig. 1 ). Thus, the minor -493T/-164C alleles are 
expressed at lower levels than the major -493G/-164T al-
leles in vivo. 
 Allele-specifi c MTTP promoter activity 
 In contrast to the above in vivo result, our previous in 
vitro results showed that the minor -493T allele has in-
creased promoter activity compared with the -493G allele 
when using minimal promoter constructs ( 13 ). Inasmuch 
as the -493G>T and -164T>C polymorphisms are on the 
same haplotype, we set out to determine whether the 
-164T>C SNP infl uences transcriptional activity per se or 
in combination with the -493G>T SNP. For this purpose, 
transient transfection assays were performed in a hepa-
toma cell line (HepG2) that endogenously expresses 
MTTP. Transfections using minimal promoter constructs 
spanning only the -164 site showed that the minor -164C 
allele conferred a 30% decrease in transcriptional activity 
compared with the major -164T allele ( P = 0.004) ( Fig. 2 ).
Constructs containing both the minor -493T and the -164C 
alleles (-593 to +27) also resulted in a 30% decrease in 
transcriptional activity compared with constructs contain-
ing both major -493G/-164T alleles ( P = 0.02) ( Fig. 2 ). In-
 Fig.  1. In vivo allele-specifi c gene expression of  MTTP in heart, 
liver, and macrophages. The pyrosequencing assay measured the 
relative amount (%) of the major 128Ile and the minor 128Thr al-
leles in heterozygous individuals, thus revealing the allele-specifi c 
effect on gene expression of the -493G>T and the -164T>C poly-
morphisms. Measurement on DNA from the same individuals is 
included as controls and showed a perfect 50:50 allele ratio as ex-
pected, refl ecting the two chromosomes. Allele ratios measured on 
the cDNA (generated from RNA isolated from subjects heterozy-
gous for the three SNPs) show that the minor -493T/-164C alleles 
have a lower transcriptional activity compared with the major al-
leles (-493G/-164T). Measurements were performed in triplicate 
on at least two different occasions for each subject. Bars indicate 
mean ± SD. 
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with the results based on EMSA experiments, the presence 
of C/EBP  and C/EBP  increased the transcriptional activ-
ity for the major -493G/-164T alleles compared with the mi-
nor -493T/-164C alleles ( Fig. 5 ). We conclude that C/EBP  
and C/EBP  are critical for the effect on transcriptional 
activity mediated by the -164T>C polymorphism. 
 Association of the MTTP -164T>C promoter 
polymorphism with IHD 
 The relationship between the -164T>C SNP and IHD 
was investigated in a Swedish case-control cohort (INTER-
GENE) consisting of 544 patients and 544 sex- and age-
matched control subjects. The subjects were genotyped 
for the -493G>T and -164T>C SNPs, which were found to 
be in perfect LD (D´ = 1.0, r 2 = 1.0). 
 The minor allele frequency of the -164T>C polymor-
phism in the  MTTP promoter was 0.25 in patients and 0.22 
in controls and the genotype distributions adhered to the 
Hardy-Weinberg equilibrium in both groups. Homozygous 
carriers of the minor -164C allele (or the -493T allele) were 
found to have a higher risk for IHD after adjustment for 
age and gender: 1.76 (1.03–2.99) [OR (95% CI)],  P = 0.038. 
The OR for heterozygous individuals was 1.13 (0.88–1.45), 
 P = 0.36. 
 DISCUSSION 
 In this study, we demonstrated an allele-specifi c expres-
sion of  MTTP predisposing to IHD. In summary, the mi-
nor alleles of the -493G>T and -164T>C SNPs conferred 
lower expression of  MTTP in the human heart, liver, and 
macrophages. In vitro experiments revealed that the 
minor -164C allele is critical in mediating the lower tran-
scriptional activity. C/EBP did not bind to the minor -164C 
allele but had strong affi nity for the major -164T allele. 
Finally, homozogosity for the -164C allele was associated 
with increased risk of IHD. On the basis of these results, 
we propose that the -164T>C SNP alters the  MTTP expres-
sion and, thus, infl uences the susceptibility to IHD. 
 The major -164T allele oligonucleotide bound more 
strongly to nuclear factors compared with the minor -164C 
allele oligonucleotide. A 100-fold excess of an unlabeled 
-164T oligonucleotide competed against this binding 
whereas a nonspecifi c DNA sequence had no effect on the 
binding ( Fig. 3B ). 
 Competitive EMSA with labeled C/EBP consensus oli-
gonucleotide and -164T and -164C oligonucleotides 
showed that an excess of unlabeled C/EBP oligonucle-
otide competes the binding of nuclear factors to the -164T 
oligonucleotide. In contrast, we could not detect any bind-
ing of C/EBP to the -164C allele ( Fig. 3C ). 
 The SRE across the -164 polymorphic site, similar to the 
one found in the  LDLR promoter, is known to bind 
SREBP-1 ( 19 ). The binding of SREBP-1 to the polymor-
phic site at position -164 was investigated using nuclear 
extracts from HepG2 cells overexpressing SREBP-1. The 
LDLR-SRE consensus oligonucleotide was used as a posi-
tive control. Supplementation with SREBP-1 antibody gen-
erated a clear supershift of the LDLR-SRE complex but no 
supershift was detected for the nuclear complexes con-
taining the -164T or the -164C oligonucleotides ( Fig. 4A , 
B ). These results indicate that C/EBP bound more strongly 
to the major -164T allele than the minor -164C allele and 
that SREBP-1 did not bind to the -164 polymorphic site in 
an allele-specifi c manner. 
 C/EBPs mediate allele-specifi c gene expression of the 
MTTP gene 
 In order to investigate if C/EBPs affect the promoter 
activity of  MTTP  per se in an allele-specifi c manner, tran-
sient transfection assays were performed in HeLa cells. 
HeLa cells do not have endogenous expression of MTTP, 
which minimizes the background signals and allows detec-
tion of any direct infl uences of C/EBPs on the transcription 
of the two promoter variants (i.e., -493G/-164T and -493T/-
164C), respectively. For this purpose, HeLa cells were 
cotransfected with pGL3-basic containing the promoter 
constructs (-593 to +27) and expression vectors containing 
C/EBP  , C/EBP  , or C/EBP  , respectively. In accordance 
 Fig.  2. Transcriptional activity of  MTTP promoter constructs. Relative luciferase activity from constructs 
spanning the -164T>C polymorphic site from position -179 to -148 in the  MTTP promoter and from con-
structs spanning both the -164T>C and -493G>T polymorphic site (-593 to +27). All constructs were tran-
siently transfected into the human HepG2 liver cell line. Cells transfected with longer promoter constructs 
were also cultured in the presence of 100 mM insulin for 24 h. Constructs containing the major allele(s) 
were set to 100% and used as reference. Bars indicate mean ± SEM. All assays were performed in triplicate. 
Empty pGL3-vector was used as control. 
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 It is postulated that MTTP is important in the heart for 
secretion of intracellular lipids, which may be toxic to the 
myocardium at high concentration ( 5, 20 ). The fi nding 
that the minor -164C allele conferred decreased MTTP 
mRNA expression compared with the major -164T allele is 
consistent with our previous study showing that individu-
als carrying the -493T allele, and hence also the minor 
-164C allele, have lower MTTP mRNA concentrations in 
the atrium of the heart compared with carriers of the com-
mon allele ( 6 ). Of note, homozygote individuals also had 
electrocardiogram abnormalities independent of preexist-
ing heart disease ( 6 ). Furthermore, it has been shown that 
decreased transcription of MTTP mRNA is inversely cor-
related with intracellular TAG concentrations in human 
hearts ( 5 ). Cardiac lesions and excessive deposition of 
lipochrome pigment have been reported in abetalipopro-
teinema, a rare recessive monogenic disease caused by mu-
tation in  MTTP ( 21, 22 ). Furthermore, tissue-specifi c 
knockout mice that lack  MTTP expression in the heart 
show cardiac lipid accumulation ( 4 ). Taken together, 
these results suggest that a functional MTTP protein is im-
portant for cardiac lipid metabolism and that the minor 
 Fig.  3. Allele-specifi c binding of nuclear factor to the -164 poly-
morphic site. A: DNA sequence from position -173 to -156 in the 
 MTTP promoter. The -164T>C site is shadowed in gray. Sequence 
containing the major T-allele shows homology to the C/EBP binding 
site as predicted by MatInspector. The C-allele sequence shows ho-
mology to the LDLR-SRE ( 9 ). The core sequence for C/EBP bind-
ing site is 5 ′ -ATTGCGCAAT and the binding site for the LDLR-SRE 
is 5 ′ -ATCACCCCAC. Stars indicate homology nucleotides. B: EMSA 
with nuclear extract from the liver cell line HepG2 and radioactive 
probes with either the major -164T allele (lanes 1–5) or the minor 
-164C allele (lanes 6–10), as indicated at the top row. The nuclear 
extract was added in all lanes except 1 and 6 which contain only free 
labeled oligonucleotide. In the competition row, the minus sign ( – ) 
indicates no competition (lanes 2 and 7), T indicates competition 
with 100-fold unlabeled -164T oligonucleotide (lanes 3 and 8), C 
indicates competition with 100-fold unlabeled -164C oligonucleotide 
(lanes 4 and 9), and X shows competition with 100-fold unlabeled 
random oligonucleotide ( 5 and  10 , ). Arrows show the allele-specifi c 
binding of nuclear factors. C: EMSA with nuclear extract from the 
liver cell line Huh7, and the radioactive probe comprising the 
C/EBP consensus sequence (lanes 1–3), the major -164T allele 
(lanes 4 and 5), and the minor -164C allele (lanes 6 and 7), as indi-
cated in the top row. First lane, no nuclear extract added, only free 
labeled C/EBP oligonucleotide. Competition with 100-fold unla-
beled C/EBP consensus oligonucleotide is indicated by a plus sign 
( + ) (lanes 3, 5 and 7). Arrow indicates the binding of C/EBP. 
 Fig.  4. Binding of SREBP-1 to LDLR-SRE but not to the -164 site. 
A: EMSA with nuclear extract from the liver cell line HepG2, over-
expressing SREBP-1 and the radioactive probe comprising the 
LDLR-SRE consensus sequence (lanes 1–3), the major -164T allele 
(lanes 4 and 5) or the minor -164C allele (lanes 6 and 7), as indi-
cated in the top row. Supplementation of antibody against SREBP-1 
is indicated with plus signs ( + ) (lanes 3, 5, and 7). No nuclear ex-
tract was added in lane 1, only free labeled oligonucleotide. Arrow 
indicates the supershift with SREBP-1 antibody and the LDL-SRE 
consensus sequence. B: Magnifi cation of the supershift. Arrow indi-
cates the band representing the supershift. 
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with various degrees of liver fat content and the heart 
biopsi es from patients undergoing aortic heart valve sur-
gery. Despite this diverse background of individuals, the 
results were similar in all three tissues/groups. 
 In this study, we showed, both in vivo and in vitro, that 
the minor allele of the -164T>C SNP resulted in lower 
transcription of the gene. This is in contrast with our ear-
lier in vitro results from HepG2 cells, showing that the mi-
nor allele of the -493G>T polymorphism was associated 
with higher promoter activity compared with the major al-
lele, using minimal promoter constructs comprising only 
the -493G>T SNP ( 13 ). However, an additional effect of 
the -493G>T polymorphism cannot be excluded from 
these experiments, which would require constructs of the 
same length with only one polymorphic site included in 
each promoter construct. Nonetheless, genetic linkage 
studies have shown that these two polymorphisms are al-
ways inherited together. Rubin et al. ( 27 ) recently reported 
that the minor alleles of the -493G>T and -164T>C SNPs 
result in higher promoter activity compared with the ma-
jor alleles when Caco-2 cells originating from human intes-
tine were transfected with  MTTP promoter constructs 
spanning from -966 to -1 not including the transcriptional 
start site. However, they could not detect any signifi cant 
differences in allele-specifi c promoter activity when Huh7 
liver cells were used ( 27 ). Of note, these two promoter 
studies did not include in vivo analyses and it has recently 
been shown that in vitro analyses often fail to predict in 
vivo effects of regulatory polymorphisms ( 28 ), indicating 
the need for assessing the effect of polymorphisms in na-
tive tissues. 
 We previously reported that the Ile128Thr polymor-
phism infl uences the interaction between MTTP and 
apoB. The threonine allele had decreased thermal stabil-
ity and weakened binding to apoB compared with the iso-
leucine allele ( 29 ). Taken together, our results suggest 
that homozygosity for the minor -164C and 128Thr alleles 
has both reduced  MTTP expression and a less functional 
protein. 
 Here, we showed that the -164T>C SNP predisposed to 
IHD in a study of 544 patients and 544 control subjects. 
We also showed that the -164T>C and the -493G>T SNPs 
were in perfect allelic association. This is in agreement 
with previous results from the WOSCOPS and ULSAM 
studies where the -493TT genotype was associated with 
higher risk of IHD ( 6 ). Of note, analyses based on com-
bined data from the INTERGENE, WOSCOPS, and UL-
SAM studies yielded a common Mantel-Haenszel OR of 
1.64 (1.20–2.25) with a Cochran-Mantel-Haenszel Statistic 
of 9.49 ( P = 0.002), the odds ratios being homogeneous 
across all studies ( P = 0.14, Breslow-Day test). 
 In contrast to the above result, there was no signifi cant 
association between the -493G>T or -164T>C SNPs and 
cardiovascular end points in the Framingham Offspring 
Study (consisting of 212 IHD patients and 2,510 control 
subjects) ( 30 ) and the ECTIM study (consisting of 622 
male patients with myocardial infarction and 728 age-
matched controls from Ireland and France) ( 31 ). Possible 
explanations for the lack of association in these studies 
alleles of the three  MTTP polymorphisms examined here, 
specifi cally the -164C variant, contribute to TAG accumu-
lation in the myocardium. 
 Cardiac lipid accumulation has been proposed to con-
tribute to the high mortality following infarction in sub-
jects with T2D ( 23 ). Ischemia in the heart induces both 
 MTTP and  APOB expression in the myocardium and in-
creases cardiac lipoprotein production and  MTTP expres-
sion is negatively related to TAG storage in myocardial 
cells ( 5 ). Animal studies have shown that overexpression 
of  apob impedes cardiac TAG accumulation ( 24 ) and pro-
tects against lipotoxic cardiomyopathy ( 25 ). Furthermore, 
it has recently been shown that overexpression of  MTTP 
decreases fat accumulation and increases secretion of 
apoB100-containing particles ( 26 ), together suggesting 
that MTTP has a protective role against lipotoxicity. 
 MTTP is also expressed in antigen-presenting cells such 
as macrophages ( 3 ). In the atherosclerotic lesion, mac-
rophages internalize oxidized LDL through the scavenger 
receptor, a process eventually converting them into foam 
cells. Little is known about the function of MTTP in mac-
rophages but it is conceivable that MTTP is involved in foam 
cell formation and plaque development. In this study, the 
minor  MTTP -164C allele was associated with lower expres-
sion of  MTTP in macrophages but whether this contributes 
to foam cell formation and progression of atherosclerosis or 
plaque instability needs to be elucidated. 
 MTTP is highly expressed in the liver and is crucial for 
the formation of VLDL ( 1 ). The expression of the minor 
 MTTP -164C allele in liver deviated slightly from that of the 
major -164T allele ( Fig. 1 ), and no association between the 
-164T>C SNP and plasma lipid or lipoprotein concentra-
tions was found in the case-control cohort (data not 
shown). It seems reasonable to assume that the high con-
stitutive expression of  MTTP in the liver attenuates the 
downstream effects of the allele-specifi c gene expression 
mediated by the -164T>C SNP on plasma lipid and lipopro-
tein concentrations. Of note, the samples used in our study 
were obtained from both healthy individuals and patients. 
The monocytes were isolated from healthy individuals 
whereas the liver biopsies were obtained from individuals 
 Fig.  5. C/EBP isoforms infl uence  MTTP promoter activity in an 
allele-specifi c manner. Relative luciferase activity measured in 
HeLa cells cotransfected with luciferase pGL3-basic vector contain-
ing the  MTTP promoter spanning from position -593 to +27, and 
PMCV5 expression vectors for C/EBP  , C/EBP  , or C/EBP  . All 
assays were performed in triplicate. Bars indicate mean ± SEM. 
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might be different study designs and ethnicities. Valida-
tion in prospective studies is needed as well as more in-
depth knowledge about the function and regulation of 
MTTP in the heart and macrophages. In addition, the in-
fl uence of other polymorphisms that are in allelic associa-
tion with the studied SNPs cannot be excluded. However, 
the -493G>T, -164T>C, and Ile128Thr are in perfect LD 
and lie in a haploblock clearly distinguished from the 3 ′ 
region of the gene, including the 3 ′ -UTR in  MTTP (Sup-
plementary  Fig. II ). Any infl uences of potential functional 
polymorphisms located 3 ′ in  MTTP are, thus, unlikely. The 
-164T>C polymorphism lies in the proximal promoter of 
MTTP that has been shown to regulate the basal transcrip-
tion of the gene ( 9 ). Therefore, it is likely that the -164T>C 
polymorphism has a profound effect on the observed al-
lele-specifi c gene expression. However, other polymorphic 
sites may also affect the expression and regulation of 
 MTTP . 
 In summary, we have shown that the minor  MTTP -164C 
variant resulted in lower expression of  MTTP in the heart, 
liver, and macrophages, most likely due to a reduced bind-
ing of C/EBPs. The -164C allele was associated with 
increased risk for IHD and we postulate that lower concen-
tration of MTTP results in increased lipid accumulation in 
the myocardium and, thus, increased susceptibility to IHD. 
We hypothesize that MTTP inhibitors could have severe 
long-term side effects related to myocardial function and it 
is important not only to study MTTP in the liver, but also in 
the heart and other tissues, to fully understand its potential 
side effects when used as a drug target.  
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